Fritextsökning
Innehållstyper
-
Smartzoom 100 – The New Digital Microscope for Maximum Efficiency
Free webinar July 1, 9:00-9:45 AM CEST and 5:00-5:45 PM CEST.
-
CT technology for when the inside matters
ZEISS METROTOM 1 now at #HandsOnMetrology.
-
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
-
Roche joins Medicon Village
Roche and Medicon Village Innovation have signed an agreement for deeper collaboration. “The fact that Roche is now becoming part of this environment further st...
-
Achieve Effortless, Standardized Automation with the new ZEISS Automation Interface
Simple interfaces for automated loading of CMMs.
-
New findings on the diseases that crushed Napoleon’s army
As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...
-
Will the FDA’s new transparency policy extend to medical devices? (Part 1)
In a significant policy shift, the FDA has begun publishing Complete Response Letters (CRLs) for drug and biologic applications that were initially rejected but...
-
Billion-Dollar Deal Sends BioArctic Soaring
Swedish Alzheimer-focused company BioArctic has entered into a licensing collaboration with Novartis regarding a technology aimed at enhancing efficient drug de...
-
ZEISS receives FDA clearance for INTRABEAM 700
With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.
-
Multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow
Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform.
-
Explore 3D Testing of Deformation and Motions
Powerful measurement capabilities with the new ZEISS ARAMIS 1.
-
Positive trend for Swedish medtech exports – “We have new markets that are huge”
In 2024, Swedish exports of pharmaceuticals decreased for the first time in several years. However, the trend for medical technology looks brighter. During a se...
-
Advanced workflow automation and scalable image analysis in spatial biology
ZEISS and Concept Life Sciences announce partnership.
-
The Future of Metrology is Coming to Your Region
Join our event series.
-
Mikael Kubista back with new venture after turbulent exit
Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...
-
Explore our tailored program for Control 2025
Choose an innovation tour, or join our industry-specific guided tours.
-
Service och kalibrering av processinstrument
För att upprätthålla noggrannhet och tillförlitlighet i era mätprocesser erbjuder OEM Automatic ett omfattande utbud av service- och kalibreringstjänster. Tills...
-
Novo Nordisk appoints Mike Doustdar as new CEO
The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts –...
-
The top five most expensive drugs in 2025
New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...
-
Pharma Outsourcing – Find the Right Partner (2026)
-
Who pays for Rebecca Doe – and all of us?
Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it
-
LINK Medical recruits Swedish CEO
The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.
-
Kennedy-rådgivare vill stoppa kombovaccin för barn under fyra
Barnvaccineringen i USA är under omprövning. På torsdagen beslutade CDC:s rådgivande vaccinkommitté (ACIP) att stoppa användningen av ett av landets viktigaste ...
-
BMS and venture capital giant form new company
The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company wil...